Tagged with DIA

Czech Republic Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s marketing strategy in medical aesthetics, the company’s strongest franchise locally, and the characteristics of the Czech market when it comes…

Hungary Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.     Hungary is actually…

Hungary Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company.   We grew more than 60 percent…

Puerto Rico In Puerto Rico, approximately 16 percent of the adult population has diabetes, one the highest prevalence in the world, compared to 10 percent in the general US population. As a result, diabetes represents a significant burden to the local healthcare system and population.   To tackle the rise of diabetes,…

India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets.   We see ourselves as a company that has great capabilities and is investing big time…

Czech Republic Jan Škrha, president of the Czech Diabetes Society (ČDS), provides insight into the most crucial advances in the quality care of Diabetes, which relies on the indispensable cooperation between specialists and General Practitioners (GPs). Škrha puts a strong emphasis on the importance of early diagnosis and discusses the underestimated role…

Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…

China The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang, founder and CEO of Innogen, returned to China in 2014 with the hope of tackling this disease with Diabegone, an…

China Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the hope of becoming a world leader in pathological diagnostics in just a few years.   Our work at Absea over…

India Regulation of medical devices in India has speedily evolved in the preceding two years. Before the introduction of the Medical Device Rules, 2017 (“MDR 2017”), the regulation of medical devices and drugs was inextricably linked. In the 18 months since the MDR 2017 has come into force, the biggest challenge…

India 2019 so far has witnessed a lot of activity in the pharma space, so much so that the e-pharmacy saga – a pressing development towards the close of 2018 – has taken a temporary backseat this year. Instead, the new stars of 2019 so far have been price regulation and…

India The Indian Government has had a busy 2019 so far with respect to healthcare regulation. From passing the controversial National Medical Commission Bill, 2019 through Parliament to releasing a digital health blueprint, the Indian Government has had a very clear vision for the future of healthcare in India. That vision…